Roche Wins FDA Clearance for Sepsis Assay

Roche has scored FDA clearance for its Elecsys BRAHMS PCT assay, which is intended for sepsis risk assessment and management in patients with severe sepsis or septic shock.

The test is designed to measure procalcitonin levels in blood — a sepsis-specific biomarker — and assists in determining the 28-day mortality risk in sepsis patients, according to the company. — Anisa Jibrell